NCT04326023View on ClinicalTrials.gov

Myelodysplastic Syndrome and Acute Myeloid Leukemia Related to PARP Inhibitors (MyeloRIB)

CompletedOBSERVATIONAL
Enrollment

178

Participants

Timeline

Start Date

February 9, 2020

Primary Completion Date

March 18, 2020

Study Completion Date

May 3, 2020

Conditions
Cancer
Interventions
DRUG

PARP Inhibitors

olaparib, rucaparib, niraparib, talazoparib, veliparib

Trial Locations (1)

14000

Alexandre Joachim, Caen

All Listed Sponsors
lead

University Hospital, Caen

OTHER

NCT04326023 - Myelodysplastic Syndrome and Acute Myeloid Leukemia Related to PARP Inhibitors (MyeloRIB) | Biotech Hunter | Biotech Hunter